molecules transparent

Industry Program

Optimising patient selection
in early-stage lung cancer: evolving pathology practices and the MDT approach

Monday 24 June – 12:30 – 13:30

Monday 24 June – 12:30 – 13:30

Chair:  Alexander Yarunin, AstraZeneca

Welcome and introduction
Alexander Yarunin, Director of Molecular Diagnostics at AstraZeneca

Molecular pathology in the setting of early-stage NSCLC: exploring contrasts in practice with advanced disease
Paul Hofman, Nice Sophia Antipolis University, France

Navigating diagnostic dilemmas in early-stage NSCLC: the MDT approach
Beatriz Bellosillo
Edurne Arriola Aperribay

Interactive discussion

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments

Tuesday 25 June – 9:45 – 10:45

Tuesday 25 June – 9:45 – 10:45
Chair:  Parth Sitlani, Invivoscribe Associate Director, Commercial – EMEA & APAC

Welcome and introduction
Parth Sitlani Invivoscribe

Beyond systematic memory B-cell archiving: Mining B-cell receptor repertoires for antigen-specific clones and tumor cell precursors
Dr. Artur Kibler, Institute of Cell Biology, University of Duisburg-Essen, Essen, Germany

Implementation of NGS-based clonality and MRD testing in a high throughput environment
Wayne Yu, Memorial Sloan Kettering Cancer Center, New York, NY, US

Q&A Session

From DNA to insights: Uncovering the overlooked in longitudinal cancer monitoring

Tuesday 25 June – 9:45 – 10:45

Tuesday 25 June – 9:45 – 10:45
Chair:  Chloe Ryder, PhD Product Manager – Liquid Biopsy, SOPHiA GENETICS, Rolle, Switzerland

Optimizing Acute Myeloid Leukemia monitoring: A novel NGS application for Measurable Residual Disease (MRD) assessment
Silvia Salmoiraghi, PhD Biologist, Ultra-specialist Laboratory of Clinical Pathology-Hematology, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy

Unlocking access to MSK-ACCESS®: A decentralized approach to innovative liquid biopsy technology
Chloe Ryder, PhD Product Manager – Liquid Biopsy, SOPHiA GENETICS, Rolle, Switzerland

From Detection to Action: Enhancing the Integrity of HRD Tests and Embracing ctDNA in Prostate Cancer

Tuesday 25 June – 13:00 – 14:00

Tuesday 25 June – 13:00 – 14:00
Chair:  Eva Maria Ciruelos

Welcome and introductions
Eva Maria Ciruelos

Confidence and Competence: Ensuring Excellence in HRD Testing
Nicole Pfarr, TUM · Institut für Allgemeine Pathologie und Pathologische Anatomie

ctDNAin the Spotlight: Transforming the Landscape of Prostate Cancer Diagnostics
Umberto Malapelle, University of Naples Federico II | UNINA · Department of Public Health

Hot Topics –Variant Interpretation
Begoña Vieites

Discussion, Q&A and closing remarks
Eva Maria Ciruelos

Integrating ctDNA analysis for Targeted Therapy in Metastatic Breast Cancer

Tuesday 25 June – 13:00 – 14:00

Tuesday 25 June – 13:00 – 14:00
Chair:  Dr. Pierre-Jean Lamy, Labosud-Ocbiologie, Imagenome, Montpellier, France

Why is comprehensive testing essential in cancer care?

Wednesday 26 June – 13:00 – 14:00

Wednesday 26 June – 13:00 – 14:00
Chair:  Kara O’Brien, Novartis, Executive Director, Global Precision Diagnostics

Welcome & PCC Overview
Kara O’Brien, Executive Director, Global Precision Diagnostics, Novartis

The overwhelming data in support of the use of comprehensive genomic testing to improve patient outcomes
Elena Castro, Medical Oncologist, Hospital 12 de Octubre, Madrid, Spain

Implementing comprehensive testing into routine practice
Fernando Lopez-Rios, Chief of Molecular Diagnostic, Service“12 de Octubre” University Hospital, Madrid, Spain

The role of tissue and liquid biopsy in comprehensive testing
Paul Hofman, Professor of Pathology and Head of the Laboratory of clinical and Experimental Pathology, Nice Sophia Antipolis University, France

Discussion, Q&A 

Kara O’Brien, Executive Director, Global Precision Diagnostics, Novartis

Federico Monzon

Federico A. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests, including leading studies on prostate and renal cancer genomics and the validation of one of the first FDA-cleared gene expression clinical assays for the diagnosis of tumors of unknown origin while at the University of Pittsburgh and Houston Methodist Hospital. At Invitae and Baylor Genetics laboratories, he pioneered the use of panel testing for hereditary cancers as well as cancer exome sequencing.

Dr. Monzon is a consultant on medical and scientific strategy for companies in the diagnostic space. Currently, he is Chief Medical Officer (CMO) at Delphi Diagnostics, a laboratory focused on providing genomic tools for the management of breast cancer patients. Prior to that, he served as CMP for Castle Diagnostics and served as Medical Director of Oncology and Medical Director for Latin America at Invitae Corporation. Previously, Dr. Monzon served as Director of Pathology at the Cancer Genetics Laboratory at Baylor College of Medicine. He earned his M.D. from the Universidad Nacional Autónoma de México (UNAM) and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. Dr Monzon was the 2017 President of the Association for Molecular Pathology (AMP) and continues to be engaged in AMP and other professional societies to shape the future of clinical genomic medicine.